NCT06291805View on ClinicalTrials.gov

Phenotyping and Characterization of wtATTR-CM (TRACE 1)

RecruitingOBSERVATIONAL

Enrollment

120

Participants

Timeline

Start Date

February 20, 2024

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions

Transthyretin AmyloidosisTransthyretin Amyloid CardiomyopathyWild-Type Transthyretin-Related (ATTR)AmyloidosisQuality of Life

Trial Locations (1)

8200

RECRUITING

Aarhus University Hospital, Aarhus

Sponsors

Collaborators (1)

Novo Nordisk A/S

All Listed Sponsors

collaborator

Novo Nordisk A/S

INDUSTRY

lead

Steen Hvitfeldt Poulsen

OTHER